Corcept Faces Lawsuit for Ignoring FDA Warnings; Stock Plummets 50%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy CORT?
Source: PRnewswire
- Lawsuit Background: Hagens Berman has filed a securities class action against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in a 50% stock plunge following FDA warning disclosures.
- FDA Warnings: The lawsuit claims that while Corcept asserted its lead product relacorilant was backed by 'powerful evidence' and 'approaching approval,' the FDA had warned them multiple times about inadequate clinical data, which management allegedly ignored.
- Investor Losses: Investors are urged to apply as Lead Plaintiff by April 21, 2026, to seek compensation for significant losses incurred due to misleading statements, highlighting the urgency of the legal action.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, further underscoring the legal risks and potential financial implications facing the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 35.690
Low
50.00
Averages
91.00
High
121.00
Current: 35.690
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Deadline: Investors are reminded that the lead plaintiff deadline for the Corcept Therapeutics (NASDAQ: CORT) class action is April 21, 2026, and those who purchased shares between October 31, 2024, and December 30, 2025, may be entitled to compensation.
- No Out-of-Pocket Costs: Participants in the class action can receive compensation without any upfront fees through a contingency fee arrangement, which alleviates financial burdens and encourages broader participation among investors.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, showcasing its extensive experience and success in this field, thereby enhancing investor confidence.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials for relacorilant's NDA, leading to significant investor losses when the truth emerged, highlighting potential misconduct in the company's information disclosure practices.
See More
Corcept Faces Lawsuit for Ignoring FDA Warnings, Stock Plummets 50%
- Lawsuit Background: Hagens Berman has filed a securities class action lawsuit against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in a 50% drop in stock price.
- FDA Warnings: The lawsuit claims that while Corcept asserted its lead product candidate, relacorilant, was backed by 'powerful evidence' and nearing approval, the FDA had repeatedly warned that its clinical data was inadequate, which management allegedly ignored.
- Regulatory Compliance Issues: Under the Securities Exchange Act of 1934, Corcept is accused of making false and/or misleading statements, particularly as they proceeded with the NDA filing despite FDA's warnings of 'significant review issues', severely undermining investor confidence.
- Investor Rights Protection: Investors must apply to be lead plaintiffs by April 21, 2026, to protect their rights and seek compensation for losses, with Hagens Berman encouraging affected investors to reach out for more information.
See More
Corcept Faces Securities Class Action Lawsuit
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Corcept Therapeutics (Nasdaq: CORT) shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to protect their rights in the class action lawsuit.
- Legal Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding misleading statements about the likelihood of FDA approval for their lead product candidate, relacorilant.
- Stock Price Plunge: Following the December 31, 2025 disclosure of the FDA's Complete Response Letter regarding relacorilant, Corcept's stock price plummeted by 50.4%, from $70.20 on December 30 to $34.80, indicating severe market disappointment in the company's prospects.
- Case Background: The lawsuit, titled Allegheny County Employees’ Retirement System v. Corcept Therapeutics, No. 26-cv-01525, highlights investor concerns over corporate transparency and compliance, which could impact future investment confidence significantly.
See More
Corcept Faces Class Action Lawsuit Over Misleading FDA Claims
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in significant shareholder losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept ignored multiple warnings from the FDA regarding inadequate clinical data before submitting its NDA, misleading investors about the drug's approval prospects.
- Stock Price Plummet: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock to drop from $70.20 to $34.80, erasing over $3.6 billion in market value and reflecting a sharp decline in market trust.
- Investor Action Call: Hagens Berman urges investors who purchased Corcept stock during the class period to contact them by April 21, 2026, to discuss becoming lead plaintiffs and protecting their rights.
See More
Corcept Therapeutics Faces Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the class action lawsuit against Corcept Therapeutics, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 to $34.80, following the FDA's rejection of its new drug application, indicating a significant loss of investor confidence in the company's future prospects.
- Legal Allegations Context: The lawsuit alleges that Corcept and its executives failed to disclose material information during the class period, violating federal securities laws, which raises concerns about the company's transparency regarding the approval process for its lead product candidate, relacorilant, potentially impacting investor decisions.
- Law Firm's Role: Kahn Swick & Foti, LLC, as the plaintiff's law firm, focuses on providing legal support to investors seeking recoveries for losses due to corporate fraud or misconduct, demonstrating the firm's expertise and influence in the securities litigation market.
See More
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Corcept Therapeutics, seeking damages for investors who purchased securities between October 31, 2024, and December 30, 2025, highlighting serious concerns regarding the company's compliance and transparency.
- False Statements Allegations: The complaint alleges that the company made materially false statements regarding the strength of clinical trials, claiming they provided “powerful support” for the New Drug Application, while the FDA raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Misleading Regulatory Outlook: The lawsuit also claims that Corcept executives misled investors by conveying confidence in relacorilant's regulatory prospects, asserting no obstacles to approval, while failing to disclose known material risks, which could lead to significant investor losses.
- Investor Rights Protection: Investors have until April 21, 2026, to request lead plaintiff status, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights and interests.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Deadline: Investors are reminded that the lead plaintiff deadline for the Corcept Therapeutics (NASDAQ: CORT) class action is April 21, 2026, and those who purchased shares between October 31, 2024, and December 30, 2025, may be entitled to compensation.
- No Out-of-Pocket Costs: Participants in the class action can receive compensation without any upfront fees through a contingency fee arrangement, which alleviates financial burdens and encourages broader participation among investors.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, showcasing its extensive experience and success in this field, thereby enhancing investor confidence.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials for relacorilant's NDA, leading to significant investor losses when the truth emerged, highlighting potential misconduct in the company's information disclosure practices.
See More
Corcept Faces Lawsuit for Ignoring FDA Warnings, Stock Plummets 50%
- Lawsuit Background: Hagens Berman has filed a securities class action lawsuit against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in a 50% drop in stock price.
- FDA Warnings: The lawsuit claims that while Corcept asserted its lead product candidate, relacorilant, was backed by 'powerful evidence' and nearing approval, the FDA had repeatedly warned that its clinical data was inadequate, which management allegedly ignored.
- Regulatory Compliance Issues: Under the Securities Exchange Act of 1934, Corcept is accused of making false and/or misleading statements, particularly as they proceeded with the NDA filing despite FDA's warnings of 'significant review issues', severely undermining investor confidence.
- Investor Rights Protection: Investors must apply to be lead plaintiffs by April 21, 2026, to protect their rights and seek compensation for losses, with Hagens Berman encouraging affected investors to reach out for more information.
See More
Corcept Faces Securities Class Action Lawsuit
- Filing Deadline: ClaimsFiler reminds investors that those who purchased Corcept Therapeutics (Nasdaq: CORT) shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to protect their rights in the class action lawsuit.
- Legal Allegations: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding misleading statements about the likelihood of FDA approval for their lead product candidate, relacorilant.
- Stock Price Plunge: Following the December 31, 2025 disclosure of the FDA's Complete Response Letter regarding relacorilant, Corcept's stock price plummeted by 50.4%, from $70.20 on December 30 to $34.80, indicating severe market disappointment in the company's prospects.
- Case Background: The lawsuit, titled Allegheny County Employees’ Retirement System v. Corcept Therapeutics, No. 26-cv-01525, highlights investor concerns over corporate transparency and compliance, which could impact future investment confidence significantly.
See More
Corcept Faces Class Action Lawsuit Over Misleading FDA Claims
- Lawsuit Background: Hagens Berman has filed a class action lawsuit against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in significant shareholder losses.
- Concealed FDA Warnings: The lawsuit claims that Corcept ignored multiple warnings from the FDA regarding inadequate clinical data before submitting its NDA, misleading investors about the drug's approval prospects.
- Stock Price Plummet: On December 31, 2025, Corcept received a Complete Response Letter from the FDA, causing its stock to drop from $70.20 to $34.80, erasing over $3.6 billion in market value and reflecting a sharp decline in market trust.
- Investor Action Call: Hagens Berman urges investors who purchased Corcept stock during the class period to contact them by April 21, 2026, to discuss becoming lead plaintiffs and protecting their rights.
See More
Corcept Therapeutics Faces Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the class action lawsuit against Corcept Therapeutics, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Stock Price Plunge: On December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 to $34.80, following the FDA's rejection of its new drug application, indicating a significant loss of investor confidence in the company's future prospects.
- Legal Allegations Context: The lawsuit alleges that Corcept and its executives failed to disclose material information during the class period, violating federal securities laws, which raises concerns about the company's transparency regarding the approval process for its lead product candidate, relacorilant, potentially impacting investor decisions.
- Law Firm's Role: Kahn Swick & Foti, LLC, as the plaintiff's law firm, focuses on providing legal support to investors seeking recoveries for losses due to corporate fraud or misconduct, demonstrating the firm's expertise and influence in the securities litigation market.
See More
Class Action Filed Against Corcept Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Corcept Therapeutics, seeking damages for investors who purchased securities between October 31, 2024, and December 30, 2025, highlighting serious concerns regarding the company's compliance and transparency.
- False Statements Allegations: The complaint alleges that the company made materially false statements regarding the strength of clinical trials, claiming they provided “powerful support” for the New Drug Application, while the FDA raised concerns about the adequacy of clinical evidence, potentially undermining investor confidence.
- Misleading Regulatory Outlook: The lawsuit also claims that Corcept executives misled investors by conveying confidence in relacorilant's regulatory prospects, asserting no obstacles to approval, while failing to disclose known material risks, which could lead to significant investor losses.
- Investor Rights Protection: Investors have until April 21, 2026, to request lead plaintiff status, with the law firm promising to charge fees only upon successful recovery, demonstrating a commitment to protecting investor rights and interests.
See More
